The Expression of ZEB1 in CTCs Associated With Metastasis and Recurrence for Gastric Cancer

The Expression of Zinc Finger E-Box Binding Homeobox 1 (ZEB1) in Circulating Tumor Cells(CTCs) Associated With Metastasis and Recurrence for Gastric Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02431078

Enrollment

100

Registered

2015-04-30

Start date

2015-06-30

Completion date

2018-07-31

Last updated

2015-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Neoplasms

Keywords

CTCs, ZEB1, gastric cancer

Brief summary

The aim of this study was to investigate the expression of ZEB1 in CTCs for gastric cancer, its correlation with the clinicopathology of gastric cancer, and the role of ZEB1 in invasion and metastasis in gastric cancer.

Detailed description

Invasion and metastasis of tumors and postoperative recurrence are the main causes of death in patients with gastric cancer and are also the key factors affecting the clinical treatment and prognosis. In this study, the investigators will detect the expression of ZEB1 in different types of CTCs(epithelial,mesenchymal and mixed phenotype) for gastric cancer by CanPatrolTM2 detection technology.Our investigation of the relationship between ZEB1 and the occurrence and development as well as the invasion and metastasis of gastric cancer is expected to provide data for the prognosis and targeted therapy of gastric cancer. Approximate 100 consecutive patients with gastric cancer and CTCs(+) will be enrolled in this study.Detection of ZEB1 expression in CTCs at baseline will show the relationship between ZEB1 and clinicopathological variables. Postoperative follow-up of ZEB1 expression in CTCs will be performed every three months in the first year and every six months in the following two years. The results may indicate the role of ZEB1 in CTCs about invasion and metastasis for gastric cancer .The aim of this study is to clarify the clinical significance of ZEB1 expression in CTCs for gastric cancer.

Interventions

PROCEDURERoutine comprehensive treatment

Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Pathologically proven gastric cancer and CTCs(+). 2. Age:older than 18 years old,younger than 80 years old. 3. cT1-4a(surgically resectable tumor),N0-3,M0 at preoperative evaluation according to the American Joint Committee on Cancer(AJCC) Cancer Staging Manual Seventh Edition. 4. No obvious surgical contraindications. 5. American Society of Anesthesiology (ASA) score class I, II, or III. 6. Written informed consent.

Exclusion criteria

1. Severe mental disorder. 2. Pregnancy. 3. History of previous gastrectomy,endoscopic mucosal resection or endoscopic submucosal dissection. 4. History of unstable angina or myocardial infarction within past six months. 5. History of previous neoadjuvant chemotherapy or radiotherapy. 6. History of other malignant disease within past 5 years.

Design outcomes

Primary

Measure	Time frame
three-year disease free survival rate	Up to 3 years post-operative

Secondary

Measure	Time frame
three-year overall survival rate	Up to 3 years post-operative
metastasis and recurrence rate	Up to 3 years post-operative
baseline detection of ZEB1 expression	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026